RioDerm-003 by Rion for Radiodermatitis: Likelihood of Approval

RioDerm-003 is under clinical development by Rion and currently in Phase I for Radiodermatitis.

Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil | Psychedelic Invest

VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical

July 16, 2024

QL-325 by QLSF Biotherapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 4, 2023

AstraZeneca picks up Pfizer’s rare disease gene therapies, taps new R&D leader as Mene Pangalos steps down

AstraZeneca’s Alexion subsidiary is snapping up a suite of Pfizer’s preclinical gene therapies in a move to expand its toolkit in rare disease R&D. The

July 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.